UCP3 and thyroid hormone involvement in methamphetamine-induced hyperthermia

Biochemical Pharmacology
Jon E SpragueEdward M Mills

Abstract

Here, we determined the extent of hypothalamic-pituitary-thyroid (HPT) axis and uncoupling protein-3 (UCP3) involvement in methamphetamine (METH)-induced hyperthermia. Sprague-Dawley rats treated with METH (40mg/kg, s.c.) responded with a hyperthermic response that peaked 1h post-treatment and was sustained through 2h. After METH treatment, thyroparathyroidectomized (TX) animals developed hypothermia that was sustained for the 3h monitoring period. In TX animals supplemented for 5 days with levothyroxine (100microg/kg, s.c.), METH-induced hypothermia was eliminated and the hyperthermic response was restored. Thyroid hormone levels (T3 and T4), measured in euthyroid animals 1h after METH, remained unchanged. As seen in rats, 1h post-METH (20mg/kg, i.p.) treatment, wild-type (WT) mice developed profound hyperthermia that was sustained for 2h. In marked contrast, UCP3-/- animals developed a markedly blunted hyperthermic response at 1h compared to WT animals. Furthermore, UCP3-/- mice could not sustain this slight elevation in temperature. Two hours post-METH treatment, UCP3-/- animal temperature returned to baseline temperatures. UCP3-/- mice were also completely protected against the lethal effects of METH, whereas 40% of WT mice...Continue Reading

References

Oct 1, 1967·European Journal of Pharmacology·E Dolfini, M Kobayashi
Jul 1, 1994·Annals of Emergency Medicine·C W Callaway, R F Clark
Sep 1, 1995·Psychopharmacology·K E SabolL S Seiden
Apr 5, 2000·The Journal of Biological Chemistry·D W GongM L Reitman
Aug 22, 2002·Drug and Alcohol Review·Linda R GowingRobert L Ali
Mar 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Jon E SpragueEdward M Mills
May 20, 2003·FEBS Letters·A LanniF Goglia
Sep 17, 1960·British Medical Journal·S C JORDAN, F HAMPSON
Dec 4, 2003·Nature·Edward M MillsToren Finkel

❮ Previous
Next ❯

Citations

Jan 11, 2005·Neurotoxicity Research·H G Baumgarten, L Lachenmayer
Dec 17, 2004·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Edward M MillsJon E Sprague
Mar 31, 2009·Brain Research Reviews·Irina N Krasnova, Jean Lud Cadet
Sep 11, 2007·Drug Discovery Today·James A Dykens, Yvonne Will
Mar 29, 2006·Clinics in Laboratory Medicine·Daniel E Rusyniak, Jon E Sprague
Jul 20, 2005·Acta Physiologica Scandinavica·E SilvestriF Goglia
Nov 16, 2006·Annals of the New York Academy of Sciences·Zbigniew K BiniendaSyed F Ali
May 30, 2007·British Journal of Pharmacology·E M MillsJ E Sprague
Oct 19, 2005·Molecular and Cellular Endocrinology·T PawadeD B Ramsden
Oct 18, 2005·The Medical Clinics of North America·Daniel E Rusyniak, Jon E Sprague
Aug 11, 2011·Toxicology Letters·Sandra L HrometzJon E Sprague
Sep 9, 2015·Temperature : Multidisciplinary Biomedical Journal·Manuel Sanchez-AlavezMaria Cecilia G Marcondes
Jan 1, 2014·Temperature : Multidisciplinary Biomedical Journal·Dmitry V ZaretskyDaniel E Rusyniak
Sep 21, 2016·The Journal of Physiology·Christopher L RileyEdward M Mills
Dec 5, 2015·Endocrinology·A Solmonson, E M Mills
Mar 13, 2012·British Journal of Pharmacology·Cm HysekM E Liechti
Oct 1, 2014·Temperature : Multidisciplinary Biomedical Journal·Christine K DaoEdward M Mills
Sep 19, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Elena SilvestriAssunta Lombardi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.